GlassScriptPhysician profile
Sahityan Viswanathan
NPI 1194251793
$2,754.87
in general payments reported to CMS, 2019-2025
20 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $718 · 2024: $905 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $470.86 | 2024-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $455.57 | 2023-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $324.24 | 2023-2025 | |
| Travere Therapeutics, INC. | $191.28 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $188.32 | 2023-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $159.58 | 2023-2025 | |
| Pfizer INC. | $149.53 | 2025 | |
| Fresenius USA Marketing, INC. | $118.93 | 2024-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $97.04 | 2023-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $92.44 | 2023-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $90.20 | 2023-2025 | Jynarque |
| Novo Nordisk INC | $74.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Vifor Pharma, INC. | $70.14 | 2023-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.06 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $58.66 | 2024-2025 | Farxiga, Lokelma |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $43.21 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $31.73 | 2025 | Terlivaz |
| Apellis Pharmaceuticals, INC. | $29.47 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $25.12 | 2024 | Gattex |
| Akebia Therapeutics INC | $19.12 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahityan Viswanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.